Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2b, randomised, double-blind, placebo-controlled multicentre study to evaluate the efficacy, safety and tolerability of orally administered full-spectrum microbiome therapeutic (EBX-102-02) in participants with moderate to severe irritable bowel syndrome with constipation

Next Previous
Trial Profile

A phase 2b, randomised, double-blind, placebo-controlled multicentre study to evaluate the efficacy, safety and tolerability of orally administered full-spectrum microbiome therapeutic (EBX-102-02) in participants with moderate to severe irritable bowel syndrome with constipation

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EBX 102 02 (Primary)
  • Indications Irritable bowel syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RISE
  • Sponsors EnteroBiotix

Most Recent Events

  • 07 Jul 2026 According to an EnteroBiotix media release, first patient has been dosed in this trial. The trial will enroll patients across seven sites in the United Kingdom.
  • 07 Jul 2026 Status changed from planning to recruiting, according to an EnteroBiotix media release.
  • 29 Apr 2026 According to an EnteroBiotix media release, First patient dosing is expected in Q2 2026 with topline efficacy data expected in H2 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top